(Q22242027)

7 February 2023

2

A

Evans

A Evans

1 reference

7 February 2023

R Katzenschlager

1

R

Katzenschlager

1 reference

7 February 2023

A Manson

3

A

Manson

1 reference

7 February 2023

P N Patsalos

4

P N

Patsalos

1 reference

7 February 2023

N Ratnaraj

5

N

Ratnaraj

1 reference

7 February 2023

H Watt

6

H

Watt

1 reference

7 February 2023

L Timmermann

7

L

Timmermann

1 reference

7 February 2023

R Van der Giessen

8

R

Van der Giessen

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

7 February 2023

language of work or name

English

0 references

publication date

December 2004

0 references

published in

0 references

volume

75

0 references

issue

12

0 references

page(s)

1672-7

0 references

cites work

Domperidone and levodopa in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Worsening of levodopa-induced dyskinesias by motor and mental tasks

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Broad bean (Vicia faba)--a natural source of L-dopa--prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Traditional and complementary therapies in Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Modification of levodopa effect by systemic decarboxylase inhibition

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Isolation of l-3:4-dihydroxyphenylalanine from the seeds of Mucuna pruriens

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

[Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease--the effect of supplement therapy to gastric acid]

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Effect of the alcohol extract of the seeds of Mucuna pruriens on free radicals and oxidative stress in albino rats.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1738871

Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use

29 November 2018

1 reference

12 December 2020

Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study

1 reference

12 December 2020

Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor

1 reference

12 December 2020

Plasma concentration of levodopa in patients with Parkinson's disease

1 reference

12 December 2020

[Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].

1 reference

12 December 2020

Effect of supplemental carbidopa on bioavailability of L-dopa

1 reference

12 December 2020

Pharmacodynamics of levodopa in Parkinson's disease

1 reference

12 December 2020

-Dopa recovery from Mucuna seed

1 reference

12 December 2020

Peripheral aromaticl-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism ofl-2-14C-dopa

1 reference

12 December 2020

Low-dose olanzapine for levodopa induced dyskinesias

1 reference

12 December 2020

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

1 reference

12 December 2020

Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism

1 reference

12 December 2020

Decarboxylation of orally administered L-dopa in the human digestive tract

1 reference

12 December 2020

Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602)

1 reference

12 December 2020

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

1 reference

12 December 2020

Comparative clinical therapeutic trial with two hypolipidemic drugs: Clofibrate and nafenopin

1 reference

12 December 2020

Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.2003.028761

1 reference

1 reference

1 reference

1 reference